Bibliographic Details
| Title: |
SENP1 as a marker for cancer |
| Document Number: |
20090162846 |
| Publication Date: |
June 25, 2009 |
| Appl. No: |
12/151482 |
| Application Filed: |
May 06, 2008 |
| Abstract: |
The present invention provides methods of detecting cancer cells by detecting the quantity of SENP1 and/or telomerase in a sample. |
| Inventors: |
Holcomb, Cherie (Oakland, CA, US); Higuchi, Russell (Alameda, CA, US); Schoenbrunner, Nancy J. (Moraga, CA, US) |
| Assignees: |
Roche Molecular Systems, Inc (Alameda, CA, US) |
| Claim: |
1. A method of correlating SENP1 expression in a biological sample to the presence of cancer, the method comprising, determining the quantity of SENP1 in a biological sample from an individual having or suspected of having a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer; correlating the determined quantity of SENP1 to the presence of cancer, wherein increased quantity of SENP1 in the biological sample compared to the quantity of SENP1 in a healthy individual indicates the presence of cancer cells; thereby correlating SENP1 expression in a biological sample to the presence of cancer. |
| Claim: |
2. The method of claim 1, wherein the method further comprises recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer. |
| Claim: |
3. The method of claim 1, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample. |
| Claim: |
4. The method of claim 3, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction. |
| Claim: |
5. The method of claim 4, wherein the amplification reaction comprises at least two different oligonucleotides such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO: 1. |
| Claim: |
6. The method of claim 4, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. |
| Claim: |
7. The method of claim 6, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5′-3′ exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide. |
| Claim: |
8. The method of claim 1, wherein the method further comprises determining the quantity of telomerase in the biological sample. |
| Claim: |
9. The method of claim 8, wherein the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells. |
| Claim: |
10. A method of correlating SENP1 expression in a biological sample to the presence of cancer, the method comprising, determining the quantity of SENP1 in a biological sample from an individual; correlating the determined quantity of SENP1 to the presence of cancer, wherein increased quantity of SENP1 in the biological sample compared to the quantity of SENP1 in a healthy individual indicates the presence of cancer cells; and recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, bladder cancer, and small intestine cancer. |
| Claim: |
11. The method of claim 10, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample. |
| Claim: |
12. The method of claim 11, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction. |
| Claim: |
13. The method of claim 12, wherein the amplification reaction comprises at least two different oligonucleotides such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO: 1. |
| Claim: |
14. The method of claim 12, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. |
| Claim: |
15. The method of claim 14, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5′-3′ exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide. |
| Claim: |
16. The method of claim 11, wherein the method further comprises determining the quantity of telomerase in the biological sample. |
| Claim: |
17. The method of claim 16, wherein the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells. |
| Claim: |
18. A method of correlating SENP1 expression in a biological sample to the presence of cancer, the method comprising, determining the quantity of SENP1 in a biological sample from an individual, wherein the biological sample is selected from the group consisting of a breast biopsy, a colon biopsy, a kidney biopsy, a lung biopsy, an ovary biopsy, a pancreas biopsy, a small intestine biopsy, a bronchial lavage and a stool; and correlating the determined quantity of SENP1 to the presence of cancer, wherein increased quantity of SENP1 in the biological sample compared to the quantity of SENP1 in a healthy individual indicates the presence of cancer cells; thereby correlating SENP1 expression in a biological sample to the presence of cancer. |
| Claim: |
19. The method of claim 18, wherein the biological sample is selected from the group consisting of a breast biopsy, a colon biopsy, a kidney biopsy, a lung biopsy, an ovary biopsy, a pancreas biopsy, a small intestine biopsy, and a bronchial lavage. |
| Claim: |
20. The method of claim 18, wherein the method further comprises recording a diagnosis of a cancer selected from the group consisting of breast cancer, colon cancer, kidney cancer, lung cancer, ovarian cancer, pancreatic cancer, and small intestine cancer. |
| Claim: |
21. The method of claim 18, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample. |
| Claim: |
22. The method of claim 21, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction. |
| Claim: |
23. The method of claim 22, wherein the amplification reaction comprises at least two different oligonucleotides such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO: 1. |
| Claim: |
24. The method of claim 22, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. |
| Claim: |
25. The method of claim 24, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5′-3′ exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide. |
| Claim: |
26. The method of claim 18, wherein the method further comprises determining the quantity of telomerase in the biological sample. |
| Claim: |
27. The method of claim 26, wherein the methods further comprise comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells. |
| Claim: |
28. A method of correlating SENP1 expression and telomerase expression in a biological sample to the presence of cancer, comprising determining the quantity of SENP1 and telomerase in a biological sample from an individual, wherein the quantity of SENP1 is detected by detecting an RNA encoding SENP1 in the sample; and correlating the determined quantity of SENP1 and telomerase to the presence of cancer, wherein increased quantity of SENP1 or telomerase in the biological sample compared to the quantity of SENP1 in a healthy individual indicates the presence of cancer cells; thereby correlating SENP1 and telomerase expression in a biological sample to the presence of cancer. |
| Claim: |
29. The method of claim 28, wherein the method further comprises recording a diagnosis of a cancer. |
| Claim: |
30. The method of claim 28, wherein the quantity of SENP1 is detected by detecting a polynucleotide encoding SENP1 in the sample. |
| Claim: |
31. The method of claim 30, wherein the detection step comprises amplifying the polynucleotide in an amplification reaction. |
| Claim: |
32. The method of claim 31, wherein the amplification reaction comprises at least two different oligonucleotides such that during the amplification reaction the oligonucleotides prime amplification of at least a fragment of SEQ ID NO: 1. |
| Claim: |
33. The method of claim 31, wherein the amplification product of the amplification reaction is detected in a step comprising hybridizing a detectably-labeled oligonucleotide to the product. |
| Claim: |
34. The method of claim 31, wherein the amplification reaction comprises a template-dependent nucleic acid polymerase with 5′-3′ exonuclease activity under conditions that allow the polymerase to fragment the detectably-labeled oligonucleotide. |
| Claim: |
35. The method of claim 28, wherein the method further comprises comparing the quantity of SENP1 and telomerase in the sample to a SENP1 standard and a telomerase standard, respectively, wherein the SENP1 standard represents SENP1 in non-cancer cells and the telomerase standard represents telomerase quantities in non-cancer cells. |
| Current U.S. Class: |
435/6 |
| Current International Class: |
12 |
| Accession Number: |
edspap.20090162846 |
| Database: |
USPTO Patent Applications |
